Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
Wednesday, April 29, 2009 - 08:49
in Health & Medicine
CHICAGO, IL-Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.
Read the whole article on Science Blog
More from Science Blog
Related
- Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancerWed, 29 Apr 2009, 9:09:30 EDT
- Vitamin E, selenium and soy in combination does not prevent prostate cancerSun, 26 Apr 2009, 9:25:21 EDT
- Men treated for localized prostate cancer could benefit from pomegranate juice consumptionSun, 26 Apr 2009, 9:25:18 EDT
- Therapeutic vaccine prolongs survival and improves quality of lifeThu, 15 May 2008, 9:29:13 EDT
- American Urological Association/Engineering & Urological Society 2009 -- news tipsSun, 26 Apr 2009, 1:38:46 EDT